HSP90 Inhibition Enhances Antimitotic Drug-Induced Mitotic Arrest and Cell Death in Preclinical Models of Non-Small Cell Lung Cancer

HSP90 inhibitors are currently undergoing clinical evaluation in combination with antimitotic drugs in non-small cell lung cancer (NSCLC), but little is known about the cellular effects of this novel drug combination. Therefore, we investigated the molecular mechanism of action of IPI-504 (retaspimy...

Descripción completa

Detalles Bibliográficos
Autores principales: O'Connell, Brenda C., O'Callaghan, Katie, Tillotson, Bonnie, Douglas, Mark, Hafeez, Nafeeza, West, Kip A., Stern, Howard, Ali, Janid A., Changelian, Paul, Fritz, Christian C., Palombella, Vito J., McGovern, Karen, Kutok, Jeffery L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4277299/
https://www.ncbi.nlm.nih.gov/pubmed/25542032
http://dx.doi.org/10.1371/journal.pone.0115228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4277299/
https://www.ncbi.nlm.nih.gov/pubmed/25542032
http://dx.doi.org/10.1371/journal.pone.0115228

Ejemplares similares